Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype.

Corrado PelaiaClaudia CrimiGirolamo PelaiaSanti NolascoRaffaele CampisiEnrico HefflerGiuseppe ValentiNunzio Crimi

Published in: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2020)

Hence, our real-life data suggest that mepolizumab can represent a valid add-on therapeutic option for patients with severe eosinophilic asthma, irrespective of IgE serum concentrations, and allergic sensitization.

Keyphrases

allergic rhinitis
chronic obstructive pulmonary disease
lung function
early onset
atopic dermatitis
chronic rhinosinusitis
electronic health record
drug induced
big data
cystic fibrosis
machine learning
deep learning
artificial intelligence